logo

IVVD

Invivyd·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --

IVVD fundamentals

Invivyd (IVVD) released its earnings on Nov 6, 2025: revenue was 13.13M (YoY +41.18%), beat estimates; EPS was -0.06 (YoY +88.24%), beat estimates.
Revenue / YoY
13.13M
+41.18%
EPS / YoY
-0.06
+88.24%
Report date
Nov 6, 2025
IVVD Earnings Call Summary for Q3,2025
  • $87M Capital Raise: Funds pivotal VYD2311 trial, positioning for mid-2026 data readout.
  • 41% YoY Revenue Growth: PEMGARDA adoption drives Q3 financial performance.
  • Innovative Regulatory Path: First-ever combination of mRNA vaccine and monoclonal antibody in single study.
  • Blockbuster Potential: $3.8B annual COVID vaccine market with high patient demand for safer alternatives.
  • Pipeline Momentum: RSV and measles programs targeting unmet needs with novel mechanisms.
EPS
Revenue

Revenue & Expenses

IVVD has released its 2025 Q3 earnings report, with revenue of 13.13M, reflecting a YoY change of 41.17%, and net profit of -10.47M, showing a YoY change of 82.76%. The Sankey diagram below clearly presents IVVD's revenue sources and cost distribution.

Key Indicators

Invivyd (IVVD) key financial stats and ratios, covering profitability, financial health, and leverage.
Invivyd (IVVD)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.
Trend
Breakdown
Invivyd (IVVD)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.
Trend
Breakdown
Invivyd (IVVD)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.
Trend
Breakdown
Where does Invivyd (IVVD) generate its revenue? Explore its key revenue streams and top earning regions.
By Business
Data source:
By Region
Data source:
Track Invivyd (IVVD) Dividend Yield, Payout Ratio & Sustainability Through Its Dividend History
Payout Ratio
Dividend Yield